Until now, European cancer medicine access has often followed a fragmented pathway. A product could receive central EMA authorisation, then face separate HTA processes across Member States, each with different comparators, evidence expectations and timelines.
The EU HTA Regulation changes the sequence. For eligible new cancer medicines and advanced therapy medicinal products, the clinical evidence review is now coordinated at EU level through joint clinical assessments. National authorities will still decide pricing, reimbursement and budget impact, but they should do so with a shared clinical assessment rather than starting from scratch.
The practical question is whether this becomes an access accelerator or simply another layer in the pathway. For personalised oncology, the stakes are high. Many new cancer medicines depend on molecular testing, smaller patient groups, complex trial designs and immature long-term evidence. If the EU system clarifies evidence expectations earlier and improves alignment across countries, it could support faster and more consistent access. If not, it may expose the same old problem in a new format: scientific eligibility without system readiness.